4//SEC Filing
Valantine Hannah 4
Accession 0001470831-25-000317
CIK 0001743881other
Filed
Nov 13, 7:00 PM ET
Accepted
Nov 14, 4:50 PM ET
Size
484.3 KB
Accession
0001470831-25-000317
Insider Transaction Report
Form 4
Valantine Hannah
Director
Transactions
- Exercise/Conversion
Common Stock
2025-11-12$48.45/sh+25,484$1,234,700→ 32,949 total - Sale
Common Stock
2025-11-12$66.07/sh−25,484$1,683,728→ 7,465 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-11-12−25,484→ 25,484 totalExercise: $48.45Exp: 2031-10-24→ Common Stock (25,484 underlying)
Holdings
- 398(indirect: By Spouse)
Common Stock
Footnotes (1)
- [F1]The stock option vested and became exercisable in three annual installments after October 25, 2021.
Issuer
BridgeBio Pharma, Inc.
CIK 0001743881
Entity typeother
Related Parties
1- filerCIK 0001855608
Filing Metadata
- Form type
- 4
- Filed
- Nov 13, 7:00 PM ET
- Accepted
- Nov 14, 4:50 PM ET
- Size
- 484.3 KB